P Mathew

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Genitourin Cancer 5:144-9. 2006
  2. doi Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Urol 181:81-7; discussion 87. 2009
  3. pmc Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
    P Mathew
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, 1155 Pressler, Houston, TX 77030, USA
    Br J Cancer 99:1426-32. 2008
  4. ncbi Protracted remission of metastatic epithelioid angiosarcoma with weekly infusion of doxorubicin, paclitaxel, and cisplatin
    Paul Mathew
    Division of Cancer Medicine, MD Anderson Cancer Centre, Houston, TX 77230 1439, USA
    Lancet Oncol 7:92-3. 2006
  5. ncbi Cancer in an incarcerated population
    Paul Mathew
    Department of Internal Medicine, The University of Texas Medical Branch, Galveston, Texas, USA
    Cancer 104:2197-204. 2005
  6. ncbi Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
  7. ncbi Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, Unit 427, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 22:3323-9. 2004
  8. ncbi Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer
    Sun Jin Kim
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 98:783-93. 2006
  9. ncbi Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases
    Hisanori Uehara
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Natl Cancer Inst 95:458-70. 2003
  10. ncbi Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes
    Alan Rodney
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2143-7. 2006

Collaborators

Detail Information

Publications26

  1. ncbi Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Genitourin Cancer 5:144-9. 2006
    ..This is a phase I/II trial of thalidomide with estramustine and paclitaxel in men with androgen-independent prostate cancer (AIPC) who underwent previous chemotherapy...
  2. doi Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Urol 181:81-7; discussion 87. 2009
    ..Men with high risk localized prostate cancer were treated with platelet derived growth factor receptor inhibitor therapy, docetaxel and hormone ablation in the preoperative setting, and clinicopathological outcomes were evaluated...
  3. pmc Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
    P Mathew
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, 1155 Pressler, Houston, TX 77030, USA
    Br J Cancer 99:1426-32. 2008
    ..Rising plasma PDGF concentrations may explain and/or mark docetaxel resistance. Validation and mechanistic studies addressing these unexpected findings should anticipate a confounding influence of concurrent PDGFR inhibitor therapy...
  4. ncbi Protracted remission of metastatic epithelioid angiosarcoma with weekly infusion of doxorubicin, paclitaxel, and cisplatin
    Paul Mathew
    Division of Cancer Medicine, MD Anderson Cancer Centre, Houston, TX 77230 1439, USA
    Lancet Oncol 7:92-3. 2006
  5. ncbi Cancer in an incarcerated population
    Paul Mathew
    Department of Internal Medicine, The University of Texas Medical Branch, Galveston, Texas, USA
    Cancer 104:2197-204. 2005
    ..The challenge posed to prison health systems in the U.S. by an immense incarcerated population is significant. However, the patterns of presentation and associated mortality of cancer among the incarcerated population is unknown...
  6. ncbi Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
    ....
  7. ncbi Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, Unit 427, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 22:3323-9. 2004
    ..Our goals were to (1) evaluate the toxicity and maximum-tolerated dose of docetaxel with imatinib, and (2) evaluate the decline of prostate-specific antigen (PSA) induced by imatinib alone, and imatinib and docetaxel...
  8. ncbi Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer
    Sun Jin Kim
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 98:783-93. 2006
    ..Because tumor cells and tumor-associated endothelial cells express activated PDGFR, the primary target for imatinib has been unclear...
  9. ncbi Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases
    Hisanori Uehara
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Natl Cancer Inst 95:458-70. 2003
    ..We examined the effects of STI571, given alone or with paclitaxel (Taxol), on tumor growth in a mouse model of prostate cancer metastasis...
  10. ncbi Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes
    Alan Rodney
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2143-7. 2006
    ..The secondary objective was to evaluate the safety and tolerability of the combination of capecitabine and gemcitabine in these patients...
  11. doi A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy
    P Mathew
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 65:811-5. 2010
    ..A modular Phase I study of lenalidomide and paclitaxel in men with metastatic castration-resistant prostate cancer (CRPC) was conducted to assess PSA kinetics with lead-in lenalidomide and the feasibility of the combination...
  12. ncbi Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer
    Paul Mathew
    University of Texas M D Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, 77030, USA
    Semin Oncol 31:24-9. 2004
    ..Clinical and translational data from these studies are likely to provide additional insights into the role of imatinib in combination therapy for prostate cancer...
  13. doi Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
    A J Zurita
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030 4009, USA
    Ann Oncol 23:688-94. 2012
    ..This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients...
  14. ncbi Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma
    Nizar Tannir
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 107:497-505. 2006
    ..The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-gamma in patients with renal cell carcinoma and bone metastases...
  15. doi A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
    Nizar M Tannir
    Genitourinary Medical Oncology Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 180:867-72; discussion 872. 2008
    ..We assessed the clinical activity and safety of gemcitabine plus capecitabine in patients with metastatic renal cell cancer previously treated with immunotherapy...
  16. doi Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77239 1439, USA
    J Clin Oncol 27:3319-24. 2009
    ..We evaluated the safety and feasibility of a concurrent combination of weekly docetaxel with repeated (153)Sm-lexidronam in patients with castration-resistant prostate cancer (CRPC)...
  17. pmc Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer
    Sue Hwa Lin
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:3729-36. 2008
    ..We aimed to understand clinical implications of sErbB3 by establishing an ELISA to detect sErbB3 levels in bone marrow and plasma samples...
  18. ncbi Taxane refractory prostate cancer
    Paul Mathew
    M D Anderson Cancer Center, Houston, Texas, USA
    J Urol 178:S36-41. 2007
    ..Although docetaxel based therapy has become established as a front line therapy choice based on large, randomized studies, published studies of second line therapy for taxane refractory disease are limited...
  19. ncbi Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer
    Sun Jin Kim
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 65:3707-15. 2005
    ..The present data recommend the combination of a bisphosphonate agent with protein tyrosine kinase inhibitor and an anticycling drug for the treatment of prostate cancer bone metastasis...
  20. pmc Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms
    Zhi Gang Li
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Clin Invest 118:2697-710. 2008
    ..Androgen receptor-null cells may contribute to the castration-resistant osteoblastic progression of prostate cancer cells in bone and provide a preclinical model for studying therapies that target these cells...
  21. ncbi Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone
    Z G Li
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Oncogene 27:596-603. 2008
    ..We conclude that MDA PCa 2b induces new bone formation through Wnt canonical signaling, that LRP5 mediates this effect, and that DKK1 is involved in the balance between bone formation and resorption that determines lesion phenotype...
  22. doi Sunitinib-induced acute hemolysis without hypertension: a case report
    Rajul Jain
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Genitourin Cancer 6:122-3. 2008
    ..Prompt discontinuation of the agent resulted in resolution of this complication...
  23. ncbi T-gamma gene rearrangement and CMV mononucleosis
    P Mathew
    Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555 0565, USA
    Am J Hematol 66:64-6. 2001
    ..Acute CMV infection may mimic lymphoproliferative disease. T-gamma gene rearrangement may be part of the immune response to CMV infection and is not specific to lymphoid neoplasia...
  24. ncbi Cancer pain management in prisons: a survey of primary care practitioners and inmates
    James T Lin
    Department of Internal Medicine, The University of Texas Medical Branch, Galveston, 77030, USA
    J Pain Symptom Manage 29:466-73. 2005
    ..These results indicate the existence of unique barriers to undertreatment of cancer pain in IPs. A multidisciplinary approach involving prison authorities and practitioners is required to improve pain management in prison populations...
  25. ncbi Prison inmates and palliative care
    James Lin
    JAMA 298:2481; author reply 2481. 2007
  26. ncbi Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference
    Philip W Kantoff
    Lank Center for Genitourinary Oncology, Boston, Massachusetts, USA
    J Urol 178:S5-8; quiz S4. 2007